University of Oxford scientists te chuan virus hlauhawm tak Nipah virus Asian ram India te ang na taka nghawng thei vaccine hmasa ber chu mihringah enchhinna an nei \an ta.
ChAdOxl Nipah B vaccine hi kim 51 lai kum 18 a\anga 55 inkarah enchhin mek a ni tiin Oxford Vaccine Group te chuan an sawi a.
Nipah virus hi hlauhawm tak mai niin a kai 75% velin an thih phah anga chhut a ni a. Tun hnaiah Asia ramah a leng darh nasa a, a bik takin Singapore, Malaysia, Bangladesh leh India ah te pawh lengin nikum September khan Kerala-ah pawh a kai pakhat hmuhchhuah a ni.
Nipah virus hi bak tena an putkual theih niin hei mai bakah hian ranvulh vawk ang ten an kaiin mihringah an kaichhawn thei niin researchers te chuan an sawi.
He virus hi World Health Organization chuan priority disease a tih niin paramyxovirus family niin pathogens heng sentut te nena inlaichinna nei an ni.
Nipah virus hi kum 25 kalta khan Malaysia leh Singapore ah hmuhchhuah ni tawh mahse tun thlengin vaccine a la awm lo va, enkawl dan bik pawh hriatfiah theih a la ni lo.
“Nipah virus hi kum 1998 khan hmuhchhuah ni tawh chungin kum 25 hnuah pawh global health community ten vaccine emaw treatment emaw pawh pawm tlan theih kan la nei lo a ni” tiin trial’s Principal Investigator, Brian Angus, University of Oxford’d Nuffield Department of Medicine chuan a sawi a.
“Nunna chan phah an tam em avang leh Nipah virus hi inkaichhawn a awl em avangin priority pandemic pathofen a dah a ni a. Vaccine trial hi a hlawhtling a nih chuan a leng darh zel tur ven a ni thei dawn a, khawvelin pandemic a tawn leh theih laka vengtu a ni thei dawn bawk,” tiin Angus chuan a sawi bawk.
Natna hlauhawm Nipah Virus vaccine enchhin
